Online inquiry

IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9120MR)

This product GTTS-WQ9120MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets MUC1 gene. The antibody can be applied in Gastric Cancer research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001018016.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4582
UniProt ID P15941
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ9120MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10338MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LY 3090106
GTTS-WQ4135MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BI-505
GTTS-WQ14469MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RO-7105705
GTTS-WQ5710MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CEA TCB
GTTS-WQ10667MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ13247MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-05335810
GTTS-WQ13363MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PR-1498487
GTTS-WQ15781MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA XmAb-13676
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW